Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Cheryl A.C. Peretz; Lisa H.F. McGary; Tanya Kumar; Hunter Jackson; Jose Jacob; Robert Durruthy-Durruthy; Mark J. Levis; Alexander Perl; Benjamin J. Huang; Catherine C. Smith

doi:10.1182/bloodadvances.2020003398

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Cheryl A.C. Peretz, Lisa H.F. McGary, Tanya Kumar, Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Mark J. Levis, Alexander Perl, Benjamin J. Huang, Catherine C. Smith

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1437-1441
Number of pages	5
Journal	Blood Advances
Volume	5
Issue number	5
DOIs	https://doi.org/10.1182/bloodadvances.2020003398
State	Published - Mar 9 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2020003398

Cite this

@article{e2a39bc327854e6e9abf127c8549f755,

title = "Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib",

author = "Peretz, {Cheryl A.C.} and McGary, {Lisa H.F.} and Tanya Kumar and Hunter Jackson and Jose Jacob and Robert Durruthy-Durruthy and Levis, {Mark J.} and Alexander Perl and Huang, {Benjamin J.} and Smith, {Catherine C.}",

note = "Funding Information: This work was funded by the National Institutes of Health, National Center for Advancing Translational Sciences (award TR001871). Funding Information: Conflict-of-interest disclosure: R.D.-D. and J.J. are full-time employees of Mission Bio, Inc. M.J.L. reports consultancy and research funding FujiFilm, consultancy and honoraria from Daiichi Sankyo Inc, consultancy and honoraria from Agios and Menarini, consultancy and research funding from Novartis and Astellas, and consultancy and honoraria from Amgen. A.P. reports honoraria, advisory board, research funding from Novartis; consultancy, honoraria, and research funding from Astellas and Daiichi Sankyo; consultancy and honoraria from NewLink Genetics; consultancy from Arog; research funding from FujiFilm; consultancy and honoraria from AbbVie; consultancy from Forma; and advisory board and research funding from Loxo and Syndax. C.C.S. reports research funding from Astellas Pharma, Abbvie, Revolution Medicines, and FujiFilm. The remaining authors declare no competing financial interests.",

year = "2021",

month = mar,

day = "9",

doi = "10.1182/bloodadvances.2020003398",

language = "English (US)",

volume = "5",

pages = "1437--1441",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

AU - Peretz, Cheryl A.C.

AU - McGary, Lisa H.F.

AU - Kumar, Tanya

AU - Jackson, Hunter

AU - Jacob, Jose

AU - Durruthy-Durruthy, Robert

AU - Levis, Mark J.

AU - Perl, Alexander

AU - Huang, Benjamin J.

AU - Smith, Catherine C.

N1 - Funding Information: This work was funded by the National Institutes of Health, National Center for Advancing Translational Sciences (award TR001871). Funding Information: Conflict-of-interest disclosure: R.D.-D. and J.J. are full-time employees of Mission Bio, Inc. M.J.L. reports consultancy and research funding FujiFilm, consultancy and honoraria from Daiichi Sankyo Inc, consultancy and honoraria from Agios and Menarini, consultancy and research funding from Novartis and Astellas, and consultancy and honoraria from Amgen. A.P. reports honoraria, advisory board, research funding from Novartis; consultancy, honoraria, and research funding from Astellas and Daiichi Sankyo; consultancy and honoraria from NewLink Genetics; consultancy from Arog; research funding from FujiFilm; consultancy and honoraria from AbbVie; consultancy from Forma; and advisory board and research funding from Loxo and Syndax. C.C.S. reports research funding from Astellas Pharma, Abbvie, Revolution Medicines, and FujiFilm. The remaining authors declare no competing financial interests.

PY - 2021/3/9

Y1 - 2021/3/9

UR - http://www.scopus.com/inward/record.url?scp=85103141699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103141699&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2020003398

DO - 10.1182/bloodadvances.2020003398

M3 - Article

C2 - 33666651

AN - SCOPUS:85103141699

SN - 2473-9529

VL - 5

SP - 1437

EP - 1441

JO - Blood Advances

JF - Blood Advances

IS - 5

ER -

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this